Lactoglobulin

β-Lactoglobulin (Lactoglobulin): A Comprehensive Reference

1. Identity

Names and Classification

β-Lactoglobulin (abbreviated BLG or β-LG) is the systematic and most widely used scientific name for the protein. It is also designated Bos d 5 in the official allergen nomenclature of the World Health Organization and International Union of Immunological Societies (WHO/IUIS). The informal term lactoglobulin, as encountered in nutritional and supplementation contexts, refers to this same molecule.

β-Lactoglobulin (beta-lactoglobulin, BLG, Bos d 5) is the major whey protein of cow and sheep's milk (~3 g/L), and is also present in many other mammalian species; a notable exception being humans. It is a globular protein of the lipocalin family, with a molecular weight of 18,300 and comprising 162 amino acid residues, including a relatively high proportion of branched-chain amino acids (BCAAs).

Natural Source and Abundance

β-Lactoglobulin is defined as the most abundant whey-derived protein from bovine milk, belonging to the lipocalin family and synthesized in the mammary gland. The major protein in whey is β-lactoglobulin, followed by α-lactalbumin (β-lactoglobulin ≈ 65%, α-lactalbumin ≈ 25%, serum albumin ≈ 8%, other ≈ 2%). β-Lactoglobulin accounts for 10% of the total protein in milk and 50% of the whey protein.

Beta-lactoglobulin (Bos d 5) — a small protein with a molecular mass of 18.3 kDa — makes up to 50% of all whey proteins and 10% of whole milk proteins, but it is essentially absent in human milk.

Genetic Variants

There are two major isoforms of beta-lactoglobulin, the genetic variants A (BLGA) and B (BLGB), which differ in amino acids 64 and 118 (aspartic acid and valine in BLGA, glycine and alanine in BLGB). BLG is the most predominant protein in bovine whey and milk serum and exists in several genetic variants, the main ones in cow milk being labelled A and B.

Forms and Preparations

BLG is commercially available in several forms arising from dairy processing and fractionation:

• Whey Protein Concentrate (WPC) and Whey Protein Isolate (WPI): standard preparations in which BLG is the dominant constituent.
• Purified BLG isolate: enriched preparations obtained by ion-exchange or gel-filtration chromatography from whey.
• BLG hydrolysates: enzymatically digested forms that generate bioactive peptides. β-Lactoglobulin is an important source of biologically active peptides; these peptides are inactive within the sequence of the precursor protein but can be released by in vivo or in vitro enzymatic proteolysis.
• Holo-BLG (holoBLG): BLG loaded with micronutrient ligands — a form specifically developed and studied for immunological applications. The holoBLG lozenge used in clinical studies contains the whey protein beta-lactoglobulin combined with micronutrients: iron complexed with catechins from cocoa extract, Vitamin A, and zinc.

Under physiological conditions, BLG exists as an equilibrium mixture of monomer and dimer forms but, at its isoelectric point, the dimers can further associate to octamers.

2. Traditional and Historical Use

Pre-Scientific Dairy Tradition

Whey was discovered about 3,000 years ago. The liquid fraction of milk — whey — has been consumed and used therapeutically across multiple cultures throughout recorded history, though without any knowledge of its constituent proteins. BLG as a discrete molecular entity was not recognized until the twentieth century; consequently, there is no traditional use attributable specifically and knowingly to BLG.

BLG was recently identified within preserved kefir cheese curds associated with the mummified remains of Bronze Age Xiaohe pastoralists (ca. 1980–1450 BC) in Xinjiang, China, confirming that dairy products containing BLG were consumed thousands of years ago, even if its molecular identity was entirely unknown to those populations.

Scientific Isolation and Early Research

When β-lactoglobulin was first isolated by Palmer in 1934, there can be little doubt that nobody realized that the protein would remain something of a puzzle 85 years later. BLG, a significant component of cow's milk, is a member of the ancient and widespread protein family that came to be named the lipocalins; the protein is abundant and easily prepared so that it has served as a convenient test-bed for essentially every molecular technique from absorption spectroscopy to X-ray crystallography.

Early work on the nature of BLG showed that it contained a good distribution of essential, or indispensable, amino acids, in consequence of which it has a clear nutritional role. The broader commercial recognition of BLG's health relevance came in the late twentieth century alongside the growth of the sports nutrition and protein supplement markets, which foregrounded whey proteins as a primary source of BLG.

3. Key Constituents and Structural Features

Primary Structure

BLG has a molecular weight of 18,300 and comprises 162 amino acid residues, including a relatively high proportion of BCAAs; it contains 22 Leu, 10 Ile, and 9 Val residues in the molecule, making it one of the richest known food sources of these amino acids. β-Lactoglobulin exhibits an exceptionally high leucine content (16%) that exceeds the constituent leucine profile (~12%) of whey protein.

Three-Dimensional Structure

The structure determination by X-ray crystallization as well as by NMR techniques revealed a globular shape built up by an 8-stranded, antiparallel β-barrel with a 3-turn α-helix on the outer surface and a ninth β-strand flanking the first strand. The spatial structure of β-LG is a bucket-like structure formed by 8 antiparallel β-folds, with a hydrophobic cavity in the center and an α-helix and a β-fold outside the bucket.

BLG's distinctive β-barrel structure contributes to enhanced bioavailability and sustained amino acid availability; its acid-resistant structure enables rapid gastric transit and intestinal hydrolysis during ingestion, forming bioactive peptides.

Sulfur Chemistry

A significant feature of beta-lactoglobulin is the sulfur chemistry of this protein: in addition to two internal disulfide bridges that stabilise the protein, there is a single sulfhydryl group at Cys 121 that is buried in the protein, protected by the alpha helix. If exposed as a result of heating or other disruption of the secondary and tertiary structure of the protein, this sulfhydryl can react with other sulfhydryl groups, leading to disulfide exchange and cross-linking reactions with other beta-lactoglobulin molecules or other whey or food proteins.

Ligand Binding Properties

Its amino-acid sequence and 3-dimensional structure show that it is a lipocalin, a widely diverse family, most of which bind small hydrophobic ligands and thus may act as specific transporters, as does serum retinol binding protein. β-Lactoglobulin is a lipocalin protein and can bind many hydrophobic molecules, suggesting a role in their transport. The structures of the ligands cholesterol and vitamin D2 have been described, each bound to the central binding cavity of bovine β-LG. β-Lactoglobulin has also been shown to be able to bind iron via siderophores and thus might have a role in combating pathogens.

4. Mechanisms of Action

Leucine–mTORC1 Anabolic Pathway

β-Lactoglobulin exhibits an exceptionally high leucine content (16%) that exceeds the constituent leucine profile (~12%) of whey protein; in addition to providing substrate for the synthesis of new muscle protein, leucine also acts as a signalling molecule to trigger muscle protein synthesis (MPS) via activation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. Its high leucine content possibly makes BLG a potent activator of the mTORC1 pathway.

Proposed β-lactoglobulin (BLG)-mediated anabolic signalling in muscle activates dual pathways: (1) leucine-dependent mTOR signalling via amino acid transporters, stimulating muscle protein synthesis through 4EBP1, LC3BII, and p70S6K; and (2) insulin-mediated PI3K/AKT signalling.

Insulinotropic and Incretin-Modulating Effects

The 62% and 30% higher insulin AUC following ingestion of BLG compared to casein and whey protein, coupled with greater incretin hormone responses, may create a favorable hormonal milieu for muscle protein synthesis, aside from also stimulating glucose uptake. The underlying mechanisms may involve stimulation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and insulin secretion together with a slower gastric emptying rate.

Glucose-Lowering Mechanisms

Preclinical studies in mouse and cell models demonstrate glucose-lowering effects of BLG comparable to metformin, mediated by DPP-4 and α-glucosidase inhibition, AMPK activation and stimulation of hepatic glucose uptake. These mechanisms have been characterized in animal and cellular models; translation to human clinical endpoints remains under investigation.

Immunomodulatory Mechanisms (Holo-BLG)

BLG is a lipocalin, like many of the major allergens, but acts as a tolerogen in context with its ligands (holoBLG) by increasing intracellular iron, importing retinoic acid (RA) via the RA receptor, and activating the arylhydrocarbon receptor via transport of flavonoids such as quercetin, promoting regulatory pathways in a concerted manner. It has been demonstrated that holoBLG selectively nourishes regulatory immune cells with micronutrients, thereby fostering immune resilience and tolerance.

In contrast, ligand-free BLG (apo-BLG) behaves differently. BLG without cargo acted as an allergen in vivo and further primed human mast cells for degranulation in an antigen-independent fashion.

Bioactive Peptide Mechanisms

These peptides are inactive within the sequence of the precursor protein but can be released by in vivo or in vitro enzymatic proteolysis; once released, they play important roles in human health, including antihypertensive, antioxidant, and antimicrobial activities as well as opioid-like features and ability to decrease body cholesterol levels.

Orally administered β-lactolin has been shown to be delivered to the brain, inhibit monoamine oxidase, and increase monoamine levels in the frontal cortex and hippocampus, resulting in improvements in spatial working memory and object recognition memory in mice.

5. Scientific Evidence by Area of Use

5.1 Skeletal Muscle — Protein Synthesis and Anabolism

Research context: β-Lactoglobulin, the predominant whey protein in bovine milk, has emerged as a promising bioactive compound, rich in leucine, with metabolic and muscle anabolic properties; a narrative review synthesizes current evidence on BLG's bioactive properties specifically pertaining to its role in glucose regulation, muscle anabolic signaling and protein synthesis across preclinical and clinical studies.

Clinical evidence — BLG versus other proteins under catabolic conditions: A double-blinded randomized crossover trial (PubMed PMID 33693737) directly compared muscle protein kinetics following ingestion of BLG, casein (CAS), and whey (WHE) during controlled catabolic conditions in men. BLG increased protein synthesis, and catabolic conditions specifically stimulated the BLG-mediated increase in protein synthesis. BLG activates the mTOR pathway and stimulates muscle protein synthesis even under inflammatory conditions.

Ongoing clinical trial — disuse atrophy: A parallel, double-blind, 2-arm, randomised placebo-controlled trial has been designed to recruit 24 healthy young (18–45 years) males and females; the intervention group combines a 7-day structured resistance exercise training programme with thrice-daily dietary supplementation with 23 g of β-lactoglobulin, and the placebo group combines the same training programme with an energy-matched carbohydrate (dextrose) control. This RCT (NCT registration) was designed to assess whether BLG supplementation can mitigate disuse-induced declines in MPS.

Evidence strength: Human evidence is emerging from small crossover trials and a recently designed RCT. The mechanistic basis (leucine/mTORC1 signalling) is well-supported, and the insulinotropic superiority over WPI has been replicated in controlled trials. Larger, longer-duration confirmatory trials are needed.

5.2 Glucose Regulation and Type 2 Diabetes

Key clinical trial: Whey protein is an insulinotropic fraction of dairy that reduces postprandial glucose levels in patients with type 2 diabetes mellitus (T2DM). BLG, the largest protein fraction of whey, was previously shown to elevate insulin concentrations compared with iso-nitrogenous whey protein isolate (WPI) in healthy individuals; the hypothesis was therefore that BLG pre-meals would lower glucose levels compared with WPI in T2DM patients. Sixteen participants with T2DM were investigated using a randomized double-blinded cross-over design, with two pre-meal interventions — (i) 25 g BLG and (ii) 25 g WPI — prior to a 75 g oral glucose tolerance test (OGTT), followed by four days of continuous glucose monitoring (CGM) at home.

Outcomes: BLG increased concentrations of insulin by 10%, glucagon by 20%, and glucose by 10% compared with WPI after the OGTT (all p < 0.05). Both BLG and WPI reduced the interstitial fluid (ISF) glucose concentrations (using CGM) by 2 mM and lowered glycemic variability by 10–15% compared with tap water.

Evidence strength: One small (n=16) double-blinded randomized crossover trial in T2DM patients. BLG demonstrated greater insulinotropic effects than WPI but also a paradoxical increase in postprandial glucose compared with WPI, which the authors note warrants further mechanistic investigation. Evidence is preliminary and limited by small sample size.

5.3 Cognitive Function — β-Lactolin

β-Lactolin is a tetrapeptide (Gly-Thr-Trp-Tyr; GTWY) derived from BLG by enzymatic hydrolysis, recognized as a distinct bioactive entity within BLG research. β-Lactolin belongs to the Trp-Tyr-related β-lactopeptide family, which improve memory impairment and are abundant in Camembert and other types of cheeses fermented by Penicillium.

Randomized controlled trial: To evaluate the effects of a β-lactolin-rich whey peptide on cognitive functions in healthy older adults, 114 healthy subjects aged 50–75 were supplemented with the whey peptide or placebo for 12 weeks in a randomized, double-blinded, placebo-controlled trial design; neuropsychological tests included assessments for memory functions, attention, and general cognitive functions. In the whey peptide group, visual paired-associates I and visual cancelation tests were significantly improved compared with those in the placebo group at weeks 6 and 12 of the intervention, respectively. The dose used was daily supplements with whey peptide containing 1.6 mg of GTWY (β-lactolin).

Integrated analysis of RCT data: Tryptophan-tyrosine-related β-lactopeptides and their representative β-lactolin have been identified as agents in dairy products that improve cognitive function and memory function via the activation of the dopaminergic system in a mouse model of amnesia; previous clinical trials have shown that supplementation with β-lactolin improves memory retrieval in healthy older adults, specifically improving scores in some neuropsychological tests. Two RCTs have shown that frontal lobe cerebral blood flow during cognitive tasks was increased in the β-lactolin group compared to the placebo group; these trials suggest that supplementation with β-lactolin enhances neural activity and increases cerebral blood flow, resulting in improved memory retrieval, especially cued recall.

Safety in these trials: Thirty subjects in the placebo group and 30 subjects in the whey peptide group reported adverse events during the study, but none of these were related to the interventions; some clinical values changed slightly from baseline but were deemed clinically insignificant.

Evidence strength: Multiple small-to-medium RCTs (primarily conducted by Kirin Company, Japan, which represents a conflict-of-interest consideration) report improvements in specific memory and attention domains in healthy older adults. The integrated analysis found supportive evidence for cued recall. Independent replication by non-industry groups is limited; the effects documented are domain-specific rather than global cognitive improvements.

5.4 Allergy and Immune Resilience — Holo-BLG

Mechanistic foundation: Although β-lactoglobulin is considered a major allergen, the protective impact of the consumption of raw milk has been shown to be dependent on the protein-content of the whey fraction and thus of β-lactoglobulin; this great contrast — on the one hand an allergen, and on the other protective — has now been linked with its ability to carry micronutrients. When β-lactoglobulin carried micronutrients it acted tolerogenic and protected against allergy development; however, when the loading was missing, it turned into an allergen.

Preclinical evidence (mouse): Prophylactic treatment with holo-BLG resulted in protection against allergic sensitization and clinical reactivity in an unspecific manner; pretreatment with holo-BLG resulted in significantly lower BLG- and Bet v 1-specific antibodies and impaired antigen-presentation with significantly lower numbers of CD11c+MHCII+ cells expressing CD86; pretreatment with holo-BLG also reduced the release of Th2-associated cytokines from splenocytes in BLG-sensitized mice.

Human in vitro data: IgE binding in children allergic to milk was reduced toward holoBLG, which also impaired degranulation of mast cells; in mice, only treatments with holoBLG prevented allergic sensitization and anaphylaxis, while sustaining regulatory T cells.

Open-label pilot clinical study (cat allergy): Patients with clinically relevant cat allergy were provoked with cat allergen for 120 min in a standardized allergen exposure chamber before and after a 3-month intervention phase (holoBLG lozenge twice daily); nasal, conjunctival, bronchial, and pruritus symptoms were scored every 10 min, constituting the total symptom score; peak nasal inspiratory flow was measured every 30 min; and a titrated nasal provocation test was performed before and after the intervention. Cat allergic patients benefited from targeted micronutrition with the holoBLG lozenge; as previously seen in other allergies, holoBLG supplementation also induced immune resilience in cat allergies, resulting in significant symptom amelioration.

Evidence strength: The holo-BLG literature is mechanistically compelling but clinically early-stage. The cat allergy study was an open-label pilot without a placebo arm, and some key authors hold patents and commercial interests in the immunoBON® product. Independent, blinded, adequately powered trials are needed. The distinction between holo-BLG (tolerogenic) and apo-BLG (allergenic) is an important and scientifically substantiated concept with direct clinical implications.

5.5 Antihypertensive Effects — BLG-Derived Peptides

Studies on animals and humans have shown that α-lactalbumin and β-lactoglobulin, which are obtained from enzymatically hydrolysed whey, are able to inhibit angiotensin-converting enzyme (ACE), while lactorphins lower blood pressure by normalizing endothelial function or by an opioid receptor-dependent mechanism. The tetrapeptide β-lactorphin (Tyr-Leu-Leu-Phe) obtained by enzymatic proteolysis from β-lactoglobulin reduced blood pressure in hypertensive rats.

Evidence strength: Primarily animal (in vivo rodent) and in vitro evidence. No large-scale human RCTs specifically examining isolated BLG-derived antihypertensive peptides have been identified at this time. The evidence is suggestive but not established for human clinical benefit.

5.6 Cholesterol-Lowering Effects — BLG-Derived Peptides

Lactostatin, a novel β-lactoglobulin-derived hypocholesterolemic peptide with the amino acid sequence Ile-Ile-Ala-Glu-Lys, was reported to surpass casein hydrolysates or even β-sitosterol in terms of hypocholesterolemic action. β-Lactotensin, another hypocholesterolemic peptide obtained through enzymatic hydrolysis of β-lactoglobulin with chymotrypsin, caused a significant decrease in blood cholesterol level and LDL content in rats fed a cholesterol-enriched diet.

Evidence strength: Animal (rat) data only for these specific peptides. Human clinical evidence for BLG-specific cholesterol-lowering effects is absent from the current literature.

5.7 Antioxidant and Anti-Inflammatory Effects — BLG Hydrolysates

The anti-inflammatory properties of BLG hydrolysate produced by alcalase were observed in lipopolysaccharide-stimulated macrophage cells by a lower level of nitric oxide production and the suppression of the synthesis of pro-inflammatory cytokines; peptide sequencing revealed that 38% of the amino acids are hydrophobic and aromatic residues, which contribute to its anti-inflammatory properties; enzymatic hydrolysis of BLG under high hydrostatic pressure produces a higher yield of short bioactive peptides with potential antioxidant and anti-inflammatory effects.

Evidence strength: In vitro and cell-model data only. Human clinical evidence is absent.

6. Body Systems Associated with Lactoglobulin

• Musculoskeletal system: Muscle protein synthesis, mTORC1 activation, resistance to disuse atrophy.
• Metabolic/endocrine system: Insulinotropic effects, incretin (GLP-1, GIP) stimulation, postprandial glucose modulation, DPP-4 inhibition (preclinical).
• Immune system: Allergen-nonspecific immune tolerance via holo-BLG, regulatory T cell support, suppression of Th2-driven allergic responses.
• Central nervous system: Cognitive function, memory retrieval, attention, and frontal cortex blood flow via β-lactolin (GTWY tetrapeptide), dopaminergic and monoamine oxidase pathways.
• Cardiovascular system: ACE inhibition by hydrolysate-derived peptides (primarily preclinical).
• Nutrient transport: Carrier function for hydrophobic vitamins (retinol, vitamin D2), fatty acids, iron (via siderophores), and flavonoids.

7. Dosage Forms and Reported Dosages

The following dosages are reported directly from the cited studies and should not be interpreted as general recommendations:

• Muscle protein synthesis / catabolic conditions: The intervention group in an RCT protocol supplemented with thrice-daily dietary supplementation with 23 g of β-lactoglobulin.
• Glucose regulation (T2DM trial): 16 participants with T2DM were administered pre-meal interventions of (i) 25 g BLG and (ii) 25 g WPI prior to an oral glucose tolerance test.
• Cognitive function (β-lactolin RCT): Daily supplements with whey peptide containing 1.6 mg of GTWY (β-lactolin) were used over 12 weeks in healthy older adults aged 50–75.
• Allergy (holo-BLG lozenge): In adults, the lozenge (immunoBON®) is taken twice daily over a period of 3 months.

BLG is delivered in multiple dosage forms: protein powder (for direct dissolution or incorporation into beverages/foods), capsule and tablet formulations (for concentrated hydrolysate or peptide preparations), and lozenges (for the holo-BLG immunological preparation).

8. Safety Considerations and Interactions

Cow's Milk Allergy (CMA)

There are two main isoforms of this protein in cow's milk, the genetic variants A and B, which differ only by 2 point mutations at amino acids 64 and 118; because it is lacking from human milk, BLG has long been believed to be the most important cow's milk allergen. Beta-lactoglobulin (Bos d 5) is the most abundant cow's milk whey protein; 13 to 76% of CMA patients are found to react to this protein.

The spatial structure of β-LG is a bucket-like structure formed by 8 antiparallel β-folds with a hydrophobic cavity, an α-helix, and a β-fold outside the bucket; this stable structure makes β-LG relatively resistant to acids and proteases, and some of the protein can remain intact after digestion, thus causing allergic reactions.

Effect of Processing on Allergenicity

Thermal treatment of β-lactoglobulin at 80–100°C reduced its ability to induce histamine release from sensitized human basophils; β-lactoglobulin presents new epitopes upon heating, but at temperatures above 85°C it builds aggregates via covalent and noncovalent interactions, thus masking conformational epitopes; linear epitopes also become inaccessible in this compact structure, resulting in decreased allergenicity. Raw milk and native whey proteins have a lower allergenic potential than their processed counterparts.

Laboratory polymerization of β-lactoglobulin by microbial transglutaminase reduces its allergenicity in children and adults with an IgE-mediated cow's milk allergy.

Holo vs. Apo Distinction — Critical Safety Concept

The ligand-loading state of BLG has fundamental implications for its biological behavior. The cargo of holoBLG is decisive in preventing allergy in vivo; BLG without cargo acted as an allergen in vivo and further primed human mast cells for degranulation in an antigen-independent fashion. This means that the form of BLG present in a given preparation — whether it carries its natural ligand complement — determines whether it is likely to be tolerogenic or pro-allergenic in atopic individuals.

Absence from Human Milk

Beta-lactoglobulin is the most abundant cow's milk whey protein; it occurs in the milk of many other mammalian species but is not present in human milk. This evolutionary absence in human milk is considered a reason why BLG is recognized as foreign by the human immune system, particularly in infants, and underlies its high rate of sensitization in this population.

Exclusion Criteria in Clinical Trials

Exclusion criteria in the BLG/T2DM clinical trial included milk allergies, daily intake of protein supplements, anti-glycemic medication other than metformin, or inability to speak or understand Danish. This highlights that milk allergy is a recognized contraindication in BLG supplementation trials.

Genetic Engineering Research Directed at Allergenicity

The allergenicity of BLG has prompted biotechnological efforts: the whey protein β-lactoglobulin is a major milk allergen absent in human milk; DNA-free BLG bi-allelic knockout cows have been generated by zinc-finger nuclease mRNA, producing BLG-free milk; according to the allergenicity evaluation of BLG-free milk, it triggered lower allergic reactions, was more easily digested, and the binding of IgE from CMA patients to BLG-free milk was significantly lower than to control milk.

Adverse Events in Clinical Trials

In the 12-week cognitive function RCT, adverse events were reported in both groups, but none were related to the interventions; some clinical values changed slightly from baseline but were deemed clinically insignificant. Overall, well-controlled clinical trials of BLG supplementation in non-allergic adults have not reported clinically significant safety signals beyond those expected from dairy protein supplementation.

References

• Kontopidis G, Holt C, Sawyer L. Invited review: beta-lactoglobulin: binding properties, structure, and function. J Dairy Sci. 2004;87(4):785–796. (PubMed)
• β-Lactoglobulin — Wikipedia
• Beta-Lactoglobulin — ScienceDirect Topics (Agricultural and Biological Sciences overview)
• β-Lactoglobulin: A novel bioactive whey protein with incretin-modulating and muscle anabolic properties. Journal of Nutritional Physiology. 2025.
• Hughes A et al. The effect of combined β-lactoglobulin supplementation and resistance exercise training prior to limb immobilisation on muscle protein synthesis rates in healthy young adults: study protocol for a randomised controlled trial. Trials. 2023;24(1):401. (PMC)
• Mose M et al. Anabolic effects of oral leucine-rich protein with and without β-hydroxybutyrate on muscle protein metabolism. PubMed PMID: 34081111.
• Smedegaard SB et al. β-Lactoglobulin Elevates Insulin and Glucagon Concentrations Compared with Whey Protein — A Randomized Double-Blinded Crossover Trial in Patients with Type Two Diabetes Mellitus. Nutrients. 2021;13(2):308. (PMC)
• Bergmann KC et al. The holo beta-lactoglobulin lozenge reduces symptoms in cat allergy — Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge. Clin Transl Allergy. 2023. (PMC)
• Roth-Walter F et al. Cow's milk protein β-lactoglobulin confers resilience against allergy by targeting complexed iron into immune cells. J Allergy Clin Immunol. 2021;147(1):321–334.
• Roth-Walter F et al. Bovine Holo-Beta-Lactoglobulin Cross-Protects Against Pollen Allergies in an Innate Manner in BALB/c Mice. Front Immunol. 2021;12:611474. (PMC)
• Ano Y et al. Supplementation With Whey Peptide Rich in β-Lactolin Improves Cognitive Performance in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study. Front Neurosci. 2019;13:399. (PMC)
• Seki T et al. Effect of Whey-Derived Lactopeptide β-Lactolin on Memory in Healthy Adults: An Integrated Analysis of Data from Randomized Controlled Trials. J Nutr Health Aging. 2022.
• Ano Y et al. β-Lactolin Reduces Age-Related Inflammation and Cognitive Decline. Front Nutr. 2021;8:724134. (PMC)
• Pihlanto A. β-Lactoglobulin as source of bioactive peptides. Amino Acids. 2008;34(4):669–680.
• Corrochano AR et al. Anti-Inflammatory and Antioxidant Properties of Peptides Released from β-Lactoglobulin by High Hydrostatic Pressure-Assisted Enzymatic Hydrolysis. Nutrients. 2017;9(7):689. (PMC)
• Beta Lactoglobulin — ScienceDirect Topics (Medicine and Dentistry overview)
• Fiocchi A et al. Cow's milk allergy: From allergens to new forms of diagnosis, therapy and prevention. Pediatr Allergy Immunol. 2010. (PMC)
• Sawyer L. β-Lactoglobulin and Glycodelin: Two Sides of the Same Coin? Front Physiol. 2021;12:678080.
• Zhang X et al. β-Lactoglobulin separation from whey protein: A comprehensive review of isolation and purification techniques and future perspectives. J Dairy Sci. 2024.
• Wei J et al. Production of hypoallergenic milk from DNA-free beta-lactoglobulin (BLG) gene knockout cow using zinc-finger nucleases mRNA. Sci Rep. 2018;8(1):14306.
• Warinner C et al. Direct evidence of milk consumption from ancient human dental calculus. Sci Rep. 2014;4:7104. (PMC)
• Cicero AFG et al. Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. Br J Pharmacol. 2017;174(11):1378–1394. (PMC)